top of page
A novel immunotherapy for non-muscle invasive bladder cancer (NMIBC).
HOPEC Pharma is developing Inactivated UPEC-FimON, a first-in-class immunotherapy designed to transform the treatment of NMIBC. Our mission is to bring safe, effective, and accessible innovation to patients worldwide.
TRANSFORMING BLADDER CANCER TREATMENT
COLLABORATIONS AND PARTNERSHIPS
Strategic partnerships drive Hopec Pharma’s mission to transform bladder cancer treatment. By collaborating with leading research institutions, healthcare providers, and industry leaders, we accelerate innovation and deliver life-changing therapies to patients worldwide.
KEY ACHIEVEMENTS
bottom of page